CA2871920C - Permeable glycosidase inhibitors and uses thereof - Google Patents

Permeable glycosidase inhibitors and uses thereof Download PDF

Info

Publication number
CA2871920C
CA2871920C CA2871920A CA2871920A CA2871920C CA 2871920 C CA2871920 C CA 2871920C CA 2871920 A CA2871920 A CA 2871920A CA 2871920 A CA2871920 A CA 2871920A CA 2871920 C CA2871920 C CA 2871920C
Authority
CA
Canada
Prior art keywords
tetrahydro
pyrano
diol
thiazole
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2871920A
Other languages
English (en)
French (fr)
Other versions
CA2871920A1 (en
Inventor
Harold G. Selnick
Wenping Li
Eric Hostetler
Kun Liu
Ernest J. Mceachern
Yuanxi Zhou
Zhongyong Wei
Changwei Mu
Yaode Wang
Jiang Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alectos Therapeutics Inc
Original Assignee
Alectos Therapeutics Inc
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2012/075185 external-priority patent/WO2013166654A1/en
Application filed by Alectos Therapeutics Inc, Merck Sharp and Dohme LLC filed Critical Alectos Therapeutics Inc
Publication of CA2871920A1 publication Critical patent/CA2871920A1/en
Application granted granted Critical
Publication of CA2871920C publication Critical patent/CA2871920C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2871920A 2012-05-08 2013-05-03 Permeable glycosidase inhibitors and uses thereof Active CA2871920C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2012/075185 WO2013166654A1 (en) 2012-05-08 2012-05-08 Permeable glycosidase inhibitors and uses thereof
CNPCT/CN2012/075185 2012-05-08
US201261655641P 2012-06-05 2012-06-05
US61/655,641 2012-06-05
PCT/US2013/039377 WO2013169576A1 (en) 2012-05-08 2013-05-03 Permeable glycosidase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CA2871920A1 CA2871920A1 (en) 2013-11-14
CA2871920C true CA2871920C (en) 2021-03-09

Family

ID=49551168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871920A Active CA2871920C (en) 2012-05-08 2013-05-03 Permeable glycosidase inhibitors and uses thereof

Country Status (10)

Country Link
US (1) US9611275B2 (https=)
EP (1) EP2847199B1 (https=)
JP (1) JP6178843B2 (https=)
KR (1) KR102108586B1 (https=)
CN (1) CN104395323B (https=)
AU (1) AU2013259892B2 (https=)
BR (1) BR112014027724B1 (https=)
CA (1) CA2871920C (https=)
RU (1) RU2707292C2 (https=)
WO (1) WO2013169576A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
RU2609210C2 (ru) 2010-12-23 2017-01-31 Алектос Терапьютикс Инк. Селективные ингибиторы гликозидазы и их применение
EP2688899B1 (en) 2011-03-24 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
BR112013033098B8 (pt) 2011-06-27 2021-03-23 Alectos Therapeutics Inc inibidores de glicosidade seletivos e usos dos mesmos
EP2726468B1 (en) 2011-06-27 2017-04-12 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2890676B1 (en) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
KR20150079711A (ko) 2012-10-31 2015-07-08 알렉토스 테라퓨틱스 인크. 글리코시다아제 저해제 및 이의 용도
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
SG11201510177WA (en) 2013-06-11 2016-01-28 Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
CN109160873A (zh) * 2018-08-14 2019-01-08 重庆市化工研究院 一种芳香族烯丙基醚及其合成方法和应用
EP4217360A4 (en) * 2020-09-25 2024-08-21 Universidad de Sevilla (US) - University of Seville (US) GLYCOSIDASE INHIBITORS AND THEIR USES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1441749A1 (ru) * 1987-03-16 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ
WO2006016904A2 (en) 2004-04-14 2006-02-16 Uab Research Foundation Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock
CA2599843C (en) 2005-03-01 2013-08-27 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
CN107253970A (zh) * 2006-08-31 2017-10-17 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
AU2007291870B2 (en) * 2006-08-31 2012-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CA2732335A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
CA2737267A1 (en) 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2011140640A1 (en) * 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
TW201249848A (en) * 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012159262A1 (en) * 2011-05-24 2012-11-29 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9126957B2 (en) 2011-08-18 2015-09-08 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2015516420A (ja) 2015-06-11
US9611275B2 (en) 2017-04-04
EP2847199B1 (en) 2017-10-25
CN104395323B (zh) 2017-08-01
RU2014149183A (ru) 2016-06-27
BR112014027724A2 (https=) 2017-08-22
KR102108586B1 (ko) 2020-05-07
RU2707292C2 (ru) 2019-11-26
AU2013259892B2 (en) 2017-09-14
JP6178843B2 (ja) 2017-08-09
BR112014027724B1 (pt) 2022-05-03
EP2847199A1 (en) 2015-03-18
AU2013259892A1 (en) 2014-10-30
CA2871920A1 (en) 2013-11-14
WO2013169576A1 (en) 2013-11-14
KR20150006841A (ko) 2015-01-19
US20150152127A1 (en) 2015-06-04
CN104395323A (zh) 2015-03-04
EP2847199A4 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
CA2871920C (en) Permeable glycosidase inhibitors and uses thereof
JP6147737B2 (ja) 選択的グリコシダーゼ阻害剤およびその使用
AU2016202186B2 (en) Selective glycosidase inhibitors and uses thereof
AU2011349021B2 (en) Selective glycosidase inhibitors and uses thereof
RU2672873C2 (ru) Ингибиторы гликозидаз и их применения
WO2012061972A1 (en) Selective glycosidase inhibitors and uses thereof
WO2014100934A1 (en) Glycosidase inhibitors and uses thereof
US8901087B2 (en) Selective glycosidase inhibitors and uses thereof
WO2013166654A1 (en) Permeable glycosidase inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180501

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110